[1]
Wells, P.G.; Mackenzie, P.I.; Chowdhury, J.R.; Guillemette, C.; Gregory, P.A.; Ishii, Y.; Hansen, A.J.; Kessler, F.K.; Kim, P.M.; Chowdhury, N.R.; Ritter, J.K. Glucuronidation and the UDP-Glucuronosyltransferases in Health and Disease. Drug Metab. Dispos., 2004, 32(3), 281-290.
[2]
Conney, A.H.; Bubns, J.J. Factors Influencing Drug Metabolism. In:Advances in Pharmacology; Garattini, S.; Shore, P.A., Eds.; Academic Press Inc., 1962, Vol. 1, pp. 31-58.
[3]
Gibson, G.G.; Paul, S. Introduction to Drug Metabolism, 3rd ed; Nelson Thornes Publishers, 2001.
[4]
Wijnen, P.A.; Bekers, O.; Drent, M. Relationship between Drug-Induced Interstitial Lung Diseases and Cytochrome P450 Polymorphisms. Curr. Opin. Pulm. Med., 2010, 16(5), 496-502.
[5]
J., Belle D.; Singh, H. Genetic Factors in Drug Metabolism. Am. Fam. Physician, 2008, 77(11), 1553-1560.
[6]
Owens, I.S.; Ritter, J.K. The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 gene locus: Implications for multiple nonhemolytic familial hyperbilirubinemia phenotypes. Pharmacogenetics, 1992, 2(3), 93-108.
[7]
Ehmer, U.; Vogel, A.; Schütte, J.K.; Krone, B.; Manns, M.; Strassburg, C.C. Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology, 2004, 39(4), 970-977.
[8]
Bosma, P.J.; Chowdhury, J.R.; Bakker, C.; Gantla, S.; de Boer, A.; Oostra, B.A.; Lindhout, D.; Tytgat, G.N.; Jansen, P.L.; Oude Elferink, R.P. The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert’s Syndrome. N. Engl. J. Med., 1995, 333(18), 1171-1175.
[9]
Strassburg, C.P. Pharmacogenetics of Gilbert’s Syndrome. Pharmacogenomics, 2008, 9(6), 703-715.
[10]
Beutler, E.; Gelbart, T.; Demina, A. Racial Variability in the UDP-Glucuronosyltransferase 1 (UGT1A1) Promoter: A Balanced Polymorphism for Regulation of Bilirubin Metabolism? Proc. Natl. Acad. Sci. USA, 1998, 95(14), 8170-8174.
[11]
Padmanabhan, S. Handbook of Pharmacogenomics and Stratified Medicine, 1st ed; Sandosh Padmanabhan, 2014.
[12]
Richmond, W. The Circassian Genocide, 1st ed; Rutgers University Press, 2013.
[13]
Dweik, B. Linguistic and Cultural Maintenance Among the Chechens of Jordan. Lang. Cult. Curriculum, 2000, 13(2), 184-195.
[14]
Shami, S. Displacement, Historical Memory, and Identity: The Circassians in Jordan. Cent. Migr. Stud. Spec. issues, 1994, 11(4), 189-201.
[15]
Zhemukhov, S.N. Circassian World: Responses to the New Challenges. PONARS Eurasia, 2018, 1
[16]
Kailani, W. In: Chechens in the Middle East: Between Original and Host Cultures, Proceedings of the Caspian Studies Program, John F. Kennedy School of Government, Harvard University, September 18 2002.
[17]
Fathallah, R.M.T.; Dajani, R. Comparison of Population Based Cancer Incidence Rates among Circassians, Chechans and Arabs in Jordan (1996-2005). Asian Pac. J. Cancer Prev., 2013, 14(10), 6035-6040.
[18]
Dajani, R.; Khader, Y.S.; Fatahallah, R.; El-Khateeb, M.; Shiyab, A.H.; Hakooz, N. Diabetes Mellitus in Genetically Isolated Populations in Jordan: Prevalence, Awareness, Glycemic Control, and Associated Factors. J. Diabetes Complications, 2012, 26(3), 175-180.
[19]
Dajani, R.; Li, J.; Wei, Z.; March, M.E.; Xia, Q.; Khader, Y.; Hakooz, N.; Fatahallah, R.; El-Khateeb, M.; Arafat, A.; Saleh, T.; Dajani, A.R.; Al-Abbadi, Z.; Abdul Qader, M.; Shiyab, A.H.; Bateiha, A.; Ajlouni, K.; Hakonarson, H. Genome-Wide Association Study Identifies Novel Type II Diabetes Risk Loci in Jordan Subpopulations. PeerJ, 2017, 5, 3618.
[20]
Dajani, R.; Li, J.; Wei, Z.; Glessner, J.T.; Chang, X.; Cardinale, C.J.; Pellegrino, R.; Wang, T.; Hakooz, N.; Khader, Y.; Sheshani, A.; Zandaki, D.; Hakonarson, H. CNV Analysis Associates AKNAD1 with Type-2 Diabetes in Jordan Subpopulations. Sci. Rep., 2015, 5, 13391.
[21]
Al-Eitan, L.N.; Nassar, A.M.; Dajani, R.B.; Almomani, B.A.; Saadeh, N.A. Diabetes Mellitus in Two Genetically Distinct Populations in Jordan: A Comparison between Arabs and Circassians/Chechens Living with Diabetes. Saudi Med. J., 2017, 38(2), 163-169.
[22]
Dajani, R.; Khader, Y.S.; Hakooz, N.; Fatahalla, R.; Quadan, F. Metabolic Syndrome between Two Ethnic Minority Groups (Circassians and Chechens) and the Original Inhabitants of Jordan. Endocrine, 2013, 43(1), 112-119.
[23]
Maeda, H.; Hazama, S.; Shavkat, A.; Okamoto, K.; Oba, K.; Sakamoto, J.; Takahashi, K.; Oka, M.; Nakamura, D.; Tsunedomi, R.; Okayama, N.; Mishima, H.; Kobayashi, M. Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations. Mol. Diagn. Ther., 2014, 18(3), 333-342.
[24]
Lu, P.H.; Chen, M.B.; Wu, X.Y.; Gu, J.H.; Liu, Y.; Gu, R. Genetic Polymorphisms of UGT1A7 and Cancer Risk: Evidence From 21 Case–Control Studies. Cancer Invest., 2011, 29(10), 645-654.
[25]
Zhang, X.; Ao, G.; Wang, Y.; Yan, W.; Wang, M.; Chen, E.; Yang, F.; Yang, J. Genetic Variants and Haplotypes of the UGT1A9, 1A7 and 1A1 Genes in Chinese Han. Genet. Mol. Biol., 2012, 35(2), 428-434.
[26]
Verlaan, M.; Drenth, J.P.H.; Truninger, K.; Koudova, M.; Schulz, H.U.; Bargetzi, M.; Künzli, B.; Friess, H.; Cerny, M.; Kage, A.; Landt, O.; teMorsche, R.H.; Rosendahl, J.; Luck, W.; Nickel, R.; Halangk, J.; Becker, M.; Macek, M., Jr; Jansen, J.B.; Witt, H. Polymorphisms of UDP-Glucuronosyltransferase 1A7 Are Not Involved in Pancreatic Diseases. J. Med. Genet., 2005, 42(10), 62.
[27]
Yan, W.; Wang, Y.W.; Yang, F.F.; Wang, M.; Zhang, X.Q.; Dong, J.; Chen, E.; Yang, J. Differences in Frequencies of UGT1A9, 1A7, and 1A1 Genetic Polymorphisms in Chinese Tibetan versus Han Chinese Populations. Genet. Mol. Res., 2013, 12(4), 6454-6461.
[28]
Fu, Z.; Shrubsole, M.J.; Li, G.; Smalley, W.E.; Hein, D.W.; Chen, Z.; Shyr, Y.; Cai, Q.; Ness, R.M.; Zheng, W. Using Gene-Environment Interaction Analyses to Clarify the Role of Well-Done Meat and Heterocyclic Amine Exposure in the Etiology of Colorectal Polyps. Am. J. Clin. Nutr., 2012, 96(5), 1119-1128.
[29]
Dajani, R.; Fathallah, R.; Arafat, A. AbdulQader, M.E.; Hakooz, N.; Al-Motassem, Y.; El-Khateeb, M. Prevalence of MTHFR C677T Single Nucleotide Polymorphism in Genetically Isolated Populations in Jordan. Biochem. Genet., 2013, 51(9–10), 780-788.
[30]
Dajani, R.; Arafat, A.; Hakooz, N.; Al-Abbadi, Z.; Yousef, A.M.; El Khateeb, M.; Quadan, F. Polymorphisms in Factor II and Factor V Thrombophilia Genes among Circassians in Jordan. J. Thromb. Thrombolysis, 2013, 35(1), 83-89.
[31]
Charan, J.; Biswas, T. How to Calculate Sample Size for Different Study Designs in Medical Research? Indian J. Psychol. Med., 2013, 35(2), 121-126.
[32]
Wang, Y.; Yi, C.; Wang, Y.; Li, H.; Li, B.; Wang, D.; Du, J.; Liu, L.; Wang, X. Distribution of Uridine Diphosphate Glucuronosyltransferase 1A Polymorphisms and Their Role in Irinotecan-Induced Toxicity in Patients with Cancer. Oncol. Lett., 2017, 14(5), 5743-5752.
[33]
Barrett, J.C.; Fry, B.; Maller, J.; Daly, M.J. Haploview: Analysis and Visualization of LD and Haplotype Maps. Bioinformatics, 2005, 21(2), 263-265.
[34]
Liu, X.; Cheng, D.; Kuang, Q.; Liu, G.; Xu, W. Association of UGT1A1*28 Polymorphisms with Irinotecan-Induced Toxicities in Colorectal Cancer: A Meta-Analysis in Caucasians. Pharmacogenomics J., 2014, 14(2), 120-129.
[35]
Culley, C.L.; Kiang, T.K.L.; Gilchrist, S.E.; Ensom, M.H.H. Effect of the UGT1A1*28 Allele on Unconjugated Hyperbilirubinemia in HIV-Positive Patients Receiving Atazanavir: A Systematic Review. Ann. Pharmacother., 2013, 47(4), 561-572.
[36]
Wenning, L.A.; Petry, A.S.; Kost, J.T.; Jin, B.; Breidinger, S.A.; DeLepeleire, I.; Carlini, E.J.; Young, S.; Rushmore, T.; Wagner, F.; Lunde, N.M.; Bieberdorf, F.; Greenberg, H.; Stone, J.A.; Wagner, J.A.; Iwamoto, M. Pharmacokinetics of Raltegravir in Individuals with UGT1A1 Polymorphisms. Clin. Pharmacol. Ther., 2009, 85(6), 623-627.
[37]
Meza-Junco, J.; Chu, Q.S.C.; Christensen, O.; Rajagopalan, P.; Das, S.; Stefanyschyn, R.; Sawyer, M.B. UGT1A1 Polymorphism and Hyperbilirubinemia in a Patient Who Received Sorafenib. Cancer Chemother. Pharmacol., 2009, 65(1), 1-4.
[38]
Ghosal, A.; Hapangama, N.; Yuan, Y.; Achanfuo-Yeboah, J.; Iannucci, R.; Chowdhury, S.; Alton, K.; Patrick, J.E.; Zbaida, S. Identification of Human UDP-Glucuronosyltransferase Enzyme(s) Responsible for the Glucuronidation of Ezetimibe (Zetia). Drug Metab. Dispos., 2004, 32(3), 314-320.
[39]
Gan, J.; Chen, W.; Shen, H.; Gao, L.; Hong, Y.; Tian, Y.; Li, W.; Zhang, Y.; Tang, Y.; Zhang, H.; Humphreys, W.G. Rodrigues; A.D. Repaglinide-Gemfibrozil Drug Interaction: Inhibition of Repaglinide Glucuronidation as a Potential Additional Contributing Mechanism. Br. J. Clin. Pharmacol., 2010, 70(6), 870-880.
[40]
Ebner, T.; Remmel, R.P.; Burchell, B. Human Bilirubin UDP-Glucuronosyltransferase Catalyzes the Glucuronidation of Ethinylestradiol. Mol. Pharmacol., 1993, 43(4), 649-654.
[41]
Hu, M.; Tomlinson, B. Effects of Statin Treatments and Polymorphisms in UGT1A1 and SLCO1B1 on Serum Bilirubin Levels in Chinese Patients with Hypercholesterolaemia. Atherosclerosis, 2012, 223(2), 427-432.
[42]
Rios, G.R.; Tephly, T.R. Inhibition and Active Sites of UDP-Glucuronosyltransferases 2B7 and 1A1. Drug Metab. Dispos., 2002, 30(12), 1364-1367.
[43]
Chouinard, S.; Tessier, M.; Vernouillet, G.; Gauthier, S.; Labrie, F.; Barbier, O.; Belanger, A. Inactivation of the Pure Antiestrogen Fulvestrant and Other Synthetic Estrogen Molecules by UDP-Glucuronosyltransferase 1A Enzymes Expressed in Breast Tissue. Mol. Pharmacol., 2006, 69(3), 908-920.
[44]
Joo, J.; Kim, Y.W.; Wu, Z.; Shin, J.H.; Lee, B.; Shon, J.C.; Lee, E.Y.; Phuc, N.M.; Liu, K.H. Screening of Non-Steroidal Anti-Inflammatory Drugs for Inhibitory Effects on the Activities of Six UDP-Glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) Using LC-MS/MS. Biopharm. Drug Dispos., 2015, 36(4), 258-264.
[45]
Liu, Y.; Ramírez, J.; House, L.; Ratain, M.J. Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases. Drug Metab. Dispos., 2010, 38(1), 32-39.
[46]
Trontelj, J.; Marc, J.; Zavratnik, A.; Bogataj, M.; Mrhar, A. Effects of UGT1A1*28 Polymorphism on Raloxifene Pharmacokinetics and Pharmacodynamics. Br. J. Clin. Pharmacol., 2009, 67(4), 437-444.
[47]
Ishii, Y.; Koba, H.; Kinoshita, K.; Oizaki, T.; Iwamoto, Y.; Takeda, S.; Miyauchi, Y.; Nishimura, Y.; Egoshi, N.; Taura, F.; Morimoto, S.; Ikushiro, S.; Nagata, K.; Yamazoe, Y.; Mackenzie, P.I.; Yamada, H. Alteration of the Function of the UDP-Glucuronosyltransferase 1A Subfamily by Cytochrome P450 3A4: Different Susceptibility for UGT Isoforms and UGT1A1/7 Variants. Drug Metab. Dispos., 2014, 42(2), 229-238.
[48]
Uchaipichat, V.; Suthisisang, C.; Miners, J.O. The Glucuronidation of R- and S-Lorazepam: Human Liver Microsomal Kinetics, UDP-Glucuronosyltransferase Enzyme Selectivity, and Inhibition by Drugs. Drug Metab. Dispos., 2013, 41(6), 1273-1284.
[49]
Li, J.H. Influence of Telmisartan on the Metabolism of Glucose-Lowering Drugs. Latin American Journal of Pharmacy, 2018, 37(3), 484-488.
[50]
Lankisch, T.O.; Behrens, G.; Ehmer, U.; Mobius, U.; Rockstroh, J.; Wehmeier, M.; Kalthoff, S.; Freiberg, N.; Manns, M.P.; Schmidt, R.E.; Strassburg, C.P. Gilbert’s Syndrome and Hyperbilirubinemia in Protease Inhibitor Therapy--an Extended Haplotype of Genetic Variants Increases Risk in Indinavir Treatment. J. Hepatol., 2009, 50(5), 1010-1018.
[51]
Han, S.X.; Wang, L.; Wu, D.Q. The Association between UGT1A7 Polymorphism and Cancer Risk: A Meta-Analysis. Cancer Epidemiol., 2012, 36(4), 201-206.
[52]
Zheng, Z.; Park, J.Y.; Guillemette, C.; Schantz, S.P.; Lazarus, P. Tobacco Carcinogen-Detoxifying Enzyme UGT1A7 and Its Association With Orolaryngeal Cancer Risk. JNCI J. Natl. Cancer Inst., 2001, 93(18), 1411-1418.
[53]
Bock, K.W.; Raschko, F.T.; Gschaidmeier, H.; Seidel, A.; Oesch, F.; Grove, A.D.; Ritter, J.K. Mono- and Diglucuronide Formation from Benzo[a]Pyrene and Chrysene Diphenols by AHH-1 Cell-Expressed UDP-Glucuronosyltransferase UGT1A7. Biochem. Pharmacol., 1999, 57(6), 653-656.
[54]
Deming, S.L.; Zheng, W.; Xu, W.H.; Cai, Q.; Ruan, Z.; Xiang, Y.B.; Shu, X.O. UGT1A1 Genetic Polymorphisms, Endogenous Estrogen Exposure, Soy Food Intake, and Endometrial Cancer Risk. Cancer Epidemiol. Biomarkers Prev., 2008, 17(3), 563-570.
[55]
Wellstein, A.; Giaccone, G.; Atkins, M.B.; Sausville, E.A. Cytotoxic Drugs.InGoodman & Gilman’s: The Pharmacological Basis of Therapeutics; Brunton, L.L.; Hilal-Dandan, R.; Knollmann, B.C., Eds.; McGraw-Hill Education: New York, NY, 2017.
[56]
Cavallari, L.H.; Lam, Y.W.F. Pharmacogenetics.InPharmacotherapy: A Pathophysiologic Approach; DiPiro, J.T.; Talbert, R.L.; Yee, G.C.; Matzke, G.R.; Wells, B.G.; Posey, L.M., Eds.; The McGraw-Hill Companies: New York, NY, 2014.
[57]
Barbarino, J.M.; Haidar, C.E.; Klein, T.E.; Altman, R.B. PharmGKB Summary: Very Important Pharmacogene Information for UGT1A1. Pharmacogenet. Genomics, 2014, 24(3), 177-183.
53
4